Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

Rhea-AI Summary

BOSTON, Sept. 20, 2022 - Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022. CEO Ron Cooper will present on September 28 at 8:30 AM ET. A replay of the webcast will be available on the Albireo Investors page.
Albireo focuses on developing bile acid modulators for treating liver diseases. Its lead product, Bylvay, is FDA-approved for pruritus in progressive familial intrahepatic cholestasis (PFIC) and is being studied for other liver diseases. In Europe, Bylvay is reimbursed for PFIC.

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022. Ron Cooper, President and Chief Executive Officer of Albireo, will be presenting on September 28, 2022, at 8:30 AM ET.

A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

 

FAQ

When is Albireo Pharma's presentation at the Guggenheim Therapeutics Conference?

Albireo Pharma's presentation is scheduled for September 28, 2022, at 8:30 AM ET.

Where is the Guggenheim Therapeutics Conference being held?

The Guggenheim Therapeutics Conference is being held in Nantucket, MA, from September 27-29, 2022.

What is the focus of Albireo Pharma?

Albireo Pharma focuses on developing novel bile acid modulators to treat pediatric and adult liver diseases.

What is Bylvay and its significance?

Bylvay is Albireo's lead product, approved by the FDA for treating pruritus in PFIC, marking a significant advancement in treatment options.

Is Bylvay reimbursed in Europe?

Yes, Bylvay is reimbursed for the treatment of PFIC in several European countries, including Germany, England, and Italy.